What is the optimal therapeutic strategy in non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in patients not pretreated with P2Y12 adenosine diphosphate receptor antagonists, and why reduce the time to invasive strategy in NSTE-ACS? In this interview, John Gorcsan, Laurent Bonello, and Arjun Majithia discuss the EARLY trial (Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment).

post
Source

https://www.acc.org/latest-in-cardiology/articles/2020/11/17/12/27/accel-lite-2020nov17

Tags

Disease Condition ,Congenital Heart Disease,DCHD_Others